ClinicalTrials.gg
Enrolling by invitationNCT04561791Updated Nov 10, 2026

Evaluation of Tethered Capsule Endomicroscopy as a Screening Tool for Barrett's Esophagus in the Primary Care Setting

An interventional study of Tethered Capsule Endomicroscopy in Barrett Esophagus, Barrett's Esophagus Without Dysplasia and Barretts Esophagus With Dysplasia, sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2019, registered Aug 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
650
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Barrett Esophagus by Massachusetts General Hospital — 3 open to participants now, 6 under way, none of them phase 3. Barrett Esophagus · Massachusetts General Hospital.

Planned enrollment
Largest of 13
650 · median 50
Started
2019
the only one that year
No phase
13 of 17
3 open now
Registered
17th of 17
by date

Among the 17 studies in Barrett Esophagus by Massachusetts General Hospital, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2019, is one of 13 with no phase, and was the 17th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

3 of the 17 studies in Barrett Esophagus by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Barrett Esophagus by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The investigators will conduct a large study in the primary care clinic to determine the feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus (BE) in the primary care practice environment. The investigators are also determining the prevalence of Barrett's esophagus in a primary care practice cohort at MGH.

Read the detailed description

The investigators have developed a tethered capsule OCT device intended as an inexpensive screening tool for BE. The capsule, which is attached to a thin, flexible tether, is reusable after being processed by a standard disinfection technique. Used without sedation, the capsule is swallowed by the participant and travels in the esophagus to the gastroesophageal junction (GEJ) via peristalsis. Cross-sectional microscopic OCT images of the entire esophagus are collected during transit. The total time needed for swallowing, imaging and retrieval does not exceed 10 minutes, with a total of 30 minutes for the procedure. The investigators have tested the feasibility and the tolerability of this new OCT screening technology in 250 procedures in healthy volunteers and participants with various esophageal diseases including BE. The procedure has been safe and well tolerated. High quality microscopic images of the esophagus have been obtained in 90% of the enrolled participants.

03

Conditions studied

  • Barrett Esophagus
  • Barrett's Esophagus Without Dysplasia
  • Barretts Esophagus With Dysplasia

Browse trials for

Keywords

  • OCT
  • Optical Coherence Tomography
  • Endomicroscopy
  • Capsule Endomicroscopy
  • Tethered Capsule Endomicroscopy
  • TCE
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants registered as patients at the Assembly Row primary care practice, MGH Broadway Primary Care - Revere, or Pentucket Medical Associates
  • 18 years or older
  • Able to give
  • Participants must have no food for 1 hour before the procedure

Exclusion criteria

Exclusion Criteria:

  • Participants older than 75 years.
  • Participants with current symptoms of dysphagia
  • Participants with gastro-intestinal strictures with a diameter less than 8mm, prior GI surgery (Esophageal and/or stomach surgeries), or history of intestinal Crohn's disease
  • Pregnancy
  • Participants scheduled for an urgent care visit for the following symptoms: fever, sore throat, upper respiratory infection symptoms, nausea, vomiting, diarrhea, abdominal pain, or other symptoms as per clinical staff discretion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Feasibility of TCE & Prevalence of BE

    1. Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment 2. Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH

    Device: Tethered Capsule Endomicroscopy

Interventions

  • DeviceTethered Capsule Endomicroscopy

    Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.

06

What researchers measure

Primary outcomes

  1. Subject Tolerability of Tethered Capsule Endomicroscopy Swallow

    The study team will ask the participant about their comfort level throughout the procedure. Participants will be asked to score the tolerability of the procedure using a scoring system from 0-10. 0= the least tolerable, 10= the most tolerable. The title of the scale is Subject Tolerability Questionnaire.

    Time frame: During the single study visit (avg 30.mins), and before leaving, the participant will fill out the tolerability survey

  2. Prevalence of Barrett's esophagus within the single Primary Care Practice cohort.

    The PI will identify signs of Barrett's esophagus from the imaging data. This is a qualitative assessment performed by the PI, as this imaging technique is to novel to have standard quality grading.

    Time frame: Imaging data is collected during the procedure, and analyzed within 1 year of collection.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2027, 107 months after the start.

Of 65 non-industry interventional studies with no phase under Barrett Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 108. This study's planned 107 months is above that.

Counting every sponsor, half of 76 studies reached it within 45 months; a quarter within 23 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Sep 24, 2020
StartActual
Jan 2, 2019
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and data sharing statement
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04561791
Responsible party
Guillermo Tearney (Guillermo J. Tearney, MD, PhD, FACC, FCAP, FNAI, Massachusetts General Hospital) — Principal investigator
First posted
Sep 24, 2020
Start date
Jan 2, 2019
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Guillermo Tearney, M.D, PhD.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion